Brief: Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile
14/05/2025 16:04
May 14 (Reuters) - Enliven Therapeutics Inc ELVN.O: ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML AND ORAL PRESENTATION AT THE EHA 2025 CONGRESS ENLIVEN THERAPEUTICS INC - ELVN-001 SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE Source text: ID:nPn7pwJnCa Further company coverage: ELVN.O (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses